FI3577237T3 - Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia - Google Patents
Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia Download PDFInfo
- Publication number
- FI3577237T3 FI3577237T3 FIEP18703944.1T FI18703944T FI3577237T3 FI 3577237 T3 FI3577237 T3 FI 3577237T3 FI 18703944 T FI18703944 T FI 18703944T FI 3577237 T3 FI3577237 T3 FI 3577237T3
- Authority
- FI
- Finland
- Prior art keywords
- pca
- pcags
- prostate cancer
- value
- population
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B10/00—ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Artificial Intelligence (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Animal Behavior & Ethology (AREA)
- Evolutionary Computation (AREA)
- Public Health (AREA)
- Software Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1750080 | 2017-02-01 | ||
| PCT/EP2018/052473 WO2018141828A1 (en) | 2017-02-01 | 2018-02-01 | Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3577237T3 true FI3577237T3 (fi) | 2023-08-29 |
Family
ID=61188779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18703944.1T FI3577237T3 (fi) | 2017-02-01 | 2018-02-01 | Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190345565A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3577237B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7138112B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN110382718A (cg-RX-API-DMAC10.html) |
| DK (1) | DK3577237T3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI3577237T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018141828A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6678201B2 (ja) * | 2018-06-05 | 2020-04-08 | 日清食品ホールディングス株式会社 | 食品情報提供システム、装置、方法及びプログラム |
| GB2599198B (en) * | 2021-06-15 | 2022-12-07 | A3P Biomedical Ab | A method for determining an appropriate time interval for further diagnostic testing for prostate cancer |
| AU2023258468A1 (en) * | 2022-04-27 | 2024-12-12 | Rhy Genetype Pty Ltd | Methods of assessing risk of developing prostate cancer |
| CN120666024A (zh) * | 2025-06-16 | 2025-09-19 | 思达智检有限公司 | 前列腺癌患病及侵袭性风险评估snp标志物、前列腺癌患病及侵袭性风险评估系统及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219840A1 (en) | 2002-05-24 | 2003-11-27 | Mikolajczyk Stephen D. | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
| JP5631000B2 (ja) | 2006-10-27 | 2014-11-26 | デコード・ジェネティクス・イーエイチエフ | Ｃｈｒ８ｑ２４．２１上の癌感受性変異体 |
| CA2750062A1 (en) | 2009-01-19 | 2010-07-22 | Katrin Stedronsky | Diagnostic assays for prostate cancer using psp94 and psa biomarkers |
| WO2012029080A1 (en) | 2010-08-30 | 2012-03-08 | Decode Genetics Ehf | Sequence variants associated with prostate specific antigen levels |
| EP2611943B1 (en) | 2010-09-03 | 2017-01-04 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| EP2850432A2 (en) * | 2012-05-16 | 2015-03-25 | Phadia AB | Method for indicating the presence or non-presence of prostate cancer |
| RU2669809C2 (ru) * | 2012-11-20 | 2018-10-16 | Пхадиа Аб | Способ прогноза для индивидуумов с раком предстательной железы |
| MY182773A (en) | 2012-11-20 | 2021-02-05 | Phadia Ab | Method for indicating a presence or non-presence of aggressive prostate cancer |
| CA2940445C (en) * | 2014-03-11 | 2021-11-30 | Phadia Ab | Method for detecting a solid tumor cancer |
| CN104946786B (zh) * | 2015-07-21 | 2018-02-27 | 冯宁翰 | 一种检测前列腺癌易感性的方法及试剂盒 |
-
2018
- 2018-02-01 US US16/481,956 patent/US20190345565A1/en not_active Abandoned
- 2018-02-01 FI FIEP18703944.1T patent/FI3577237T3/fi active
- 2018-02-01 WO PCT/EP2018/052473 patent/WO2018141828A1/en not_active Ceased
- 2018-02-01 DK DK18703944.1T patent/DK3577237T3/da active
- 2018-02-01 JP JP2019541445A patent/JP7138112B2/ja active Active
- 2018-02-01 EP EP18703944.1A patent/EP3577237B1/en active Active
- 2018-02-01 CN CN201880009454.1A patent/CN110382718A/zh active Pending
-
2022
- 2022-09-05 JP JP2022140682A patent/JP2022179483A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110382718A (zh) | 2019-10-25 |
| JP2020505928A (ja) | 2020-02-27 |
| JP2022179483A (ja) | 2022-12-02 |
| EP3577237B1 (en) | 2023-07-19 |
| JP7138112B2 (ja) | 2022-09-15 |
| WO2018141828A1 (en) | 2018-08-09 |
| US20190345565A1 (en) | 2019-11-14 |
| DK3577237T3 (da) | 2023-08-28 |
| EP3577237A1 (en) | 2019-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109859801B (zh) | 一种含有七个基因作为生物标志物预测肺鳞癌预后的模型及建立方法 | |
| Prensner et al. | RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1 | |
| Sandhu et al. | Panomics for precision medicine | |
| Jeon et al. | Temporal stability and prognostic biomarker potential of the prostate cancer urine miRNA transcriptome | |
| Sung et al. | Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer | |
| Van Laar et al. | Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use | |
| Matsui | Genomic biomarkers for personalized medicine: development and validation in clinical studies | |
| JP2019049559A (ja) | 侵攻性前立腺癌の存在または不存在を判定する方法 | |
| US20150094221A1 (en) | Method for Indicating the Presence or Non-Presence of Prostate Cancer | |
| JP2014533955A (ja) | パクリタキセル応答性がんマーカー | |
| RU2015124008A (ru) | Способ прогноза для индивидуумов с раком предстательной железы | |
| Akamatsu et al. | Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese | |
| Veith et al. | Diagnosing alpha-1-antitrypsin deficiency using A PCR/luminescence-based technology | |
| Viprey et al. | Minimal disease monitoring by QRT–PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials | |
| Cano-Gamez et al. | The circulating cell-free DNA landscape in sepsis is dominated by impaired liver clearance | |
| Greco et al. | HCG18, LEF1AS1 and lncCEACAM21 as biomarkers of disease severity in the peripheral blood mononuclear cells of COVID-19 patients | |
| Moore et al. | Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients | |
| JP2020505928A5 (cg-RX-API-DMAC10.html) | ||
| Elamin et al. | A specific blood signature reveals higher levels of S100A12: a potential bladder cancer diagnostic biomarker along with urinary engrailed-2 protein detection | |
| US20190024184A1 (en) | Distinguishing metastatic-lethal prostate cancer from indolent prostate cancer using methylation status of epigenetic markers | |
| Martin | Validation of reference genes for oral cancer detection panels in a prospective blinded cohort | |
| Huang et al. | Construction and validation of a novel prognostic signature of idiopathic pulmonary fibrosis by identifying subtypes based on genes related to 7-methylguanosine modification | |
| CN113234823A (zh) | 胰腺癌预后风险评估模型及其应用 | |
| Plesingerova et al. | COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status | |
| Lu et al. | Transcriptional profiling and co-expression network analysis identifies potential biomarkers to differentiate chronic hepatitis B and the caused cirrhosis |